Death and morbidity from supratherapeutic dosing of colchicine

Michelle Sweidan, James F Reeve and Kitty Yu
Med J Aust 2011; 195 (9): . || doi: 10.5694/mja11.11117
Published online: 7 November 2011

To the Editor: We agree with Smith and colleagues1 that it is important to raise awareness among health professionals — and consumers — about recently revised dosing recommendations for colchicine. Software decision-support tools have an important role in ensuring safe prescribing of such drugs. However, we have questions about whether this software uses information that is up-to-date with current evidence, particularly in relation to colchicine.

  • Michelle Sweidan
  • James F Reeve
  • Kitty Yu

  • National Prescribing Service, Melbourne, VIC.


Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.